Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin)

V. Lorusso, A. Pagliarulo, F. P. Selvaggi, E. Durini, F. Riccardi, P. Comella, C. Fiorillo, M. De Lena

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Transitional cell carcinoma of the urinary tract is actually considered very sensitive to cisplatin-containing regimens. Nevertheless, the generally impaired renal function and poor performance status of these patients are responsible for the severe toxicity usually occurring when cisplatin, either alone or in combination with other agents, is administered to these patients. The aim of this study was to verify the possibility of substituting carbo platin for cisplatin, and epirubicin for doxorubicin in the M-VAC regimen in order to reduce toxicity and improve patient tolerance. Thirty-five patients with advanced urothelial tract carcinoma were treated with a chemotherapeutic regimen composed of methotrexate (30 mg/m 2 iv on days 1, 15, 22), vinblastine (3 mg/m 2 iv on days 2, 15, 22), epirubicin (35 mg/m 2 iv on day 2) and carboplatin (250 mg/m 2 iv on day 2) every 4 weeks (M-VECA). All patients had bidimensionally measurable disease. Of the 32 evaluable patients, 5 (16%) obtained a complete response and 10 (31%) a partial response (response rate: 47% C.I. = 30%-64%). Grade III-IV leuko-thrombocytopenia was observed in 25%, and mucositis in 19% of cases. Nevertheless, recovery was prompt and opportune dosage reductions avoided severe toxicity in subsequent cycles in most patients. In conclusion, M-VECA is a safe and effective regimen for the treatment of patients with metastatic urothelial tumors.

Original languageEnglish
Pages (from-to)154-158
Number of pages5
JournalJournal of Chemotherapy
Volume8
Issue number2
Publication statusPublished - 1996

Fingerprint

Epirubicin
Vinblastine
Carboplatin
Methotrexate
Carcinoma
Cisplatin
Therapeutics
Mucositis
Transitional Cell Carcinoma
Charcoal
Urinary Tract
Thrombocytopenia
Doxorubicin
Kidney

Keywords

  • Bladder cancer
  • Carbo platin
  • Chemotherapy
  • Epirubicin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Lorusso, V., Pagliarulo, A., Selvaggi, F. P., Durini, E., Riccardi, F., Comella, P., ... De Lena, M. (1996). Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin). Journal of Chemotherapy, 8(2), 154-158.

Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin). / Lorusso, V.; Pagliarulo, A.; Selvaggi, F. P.; Durini, E.; Riccardi, F.; Comella, P.; Fiorillo, C.; De Lena, M.

In: Journal of Chemotherapy, Vol. 8, No. 2, 1996, p. 154-158.

Research output: Contribution to journalArticle

Lorusso, V, Pagliarulo, A, Selvaggi, FP, Durini, E, Riccardi, F, Comella, P, Fiorillo, C & De Lena, M 1996, 'Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin)', Journal of Chemotherapy, vol. 8, no. 2, pp. 154-158.
Lorusso, V. ; Pagliarulo, A. ; Selvaggi, F. P. ; Durini, E. ; Riccardi, F. ; Comella, P. ; Fiorillo, C. ; De Lena, M. / Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin). In: Journal of Chemotherapy. 1996 ; Vol. 8, No. 2. pp. 154-158.
@article{c602885e31704ee8a8b28c1b4e1724b6,
title = "Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin)",
abstract = "Transitional cell carcinoma of the urinary tract is actually considered very sensitive to cisplatin-containing regimens. Nevertheless, the generally impaired renal function and poor performance status of these patients are responsible for the severe toxicity usually occurring when cisplatin, either alone or in combination with other agents, is administered to these patients. The aim of this study was to verify the possibility of substituting carbo platin for cisplatin, and epirubicin for doxorubicin in the M-VAC regimen in order to reduce toxicity and improve patient tolerance. Thirty-five patients with advanced urothelial tract carcinoma were treated with a chemotherapeutic regimen composed of methotrexate (30 mg/m 2 iv on days 1, 15, 22), vinblastine (3 mg/m 2 iv on days 2, 15, 22), epirubicin (35 mg/m 2 iv on day 2) and carboplatin (250 mg/m 2 iv on day 2) every 4 weeks (M-VECA). All patients had bidimensionally measurable disease. Of the 32 evaluable patients, 5 (16{\%}) obtained a complete response and 10 (31{\%}) a partial response (response rate: 47{\%} C.I. = 30{\%}-64{\%}). Grade III-IV leuko-thrombocytopenia was observed in 25{\%}, and mucositis in 19{\%} of cases. Nevertheless, recovery was prompt and opportune dosage reductions avoided severe toxicity in subsequent cycles in most patients. In conclusion, M-VECA is a safe and effective regimen for the treatment of patients with metastatic urothelial tumors.",
keywords = "Bladder cancer, Carbo platin, Chemotherapy, Epirubicin",
author = "V. Lorusso and A. Pagliarulo and Selvaggi, {F. P.} and E. Durini and F. Riccardi and P. Comella and C. Fiorillo and {De Lena}, M.",
year = "1996",
language = "English",
volume = "8",
pages = "154--158",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin)

AU - Lorusso, V.

AU - Pagliarulo, A.

AU - Selvaggi, F. P.

AU - Durini, E.

AU - Riccardi, F.

AU - Comella, P.

AU - Fiorillo, C.

AU - De Lena, M.

PY - 1996

Y1 - 1996

N2 - Transitional cell carcinoma of the urinary tract is actually considered very sensitive to cisplatin-containing regimens. Nevertheless, the generally impaired renal function and poor performance status of these patients are responsible for the severe toxicity usually occurring when cisplatin, either alone or in combination with other agents, is administered to these patients. The aim of this study was to verify the possibility of substituting carbo platin for cisplatin, and epirubicin for doxorubicin in the M-VAC regimen in order to reduce toxicity and improve patient tolerance. Thirty-five patients with advanced urothelial tract carcinoma were treated with a chemotherapeutic regimen composed of methotrexate (30 mg/m 2 iv on days 1, 15, 22), vinblastine (3 mg/m 2 iv on days 2, 15, 22), epirubicin (35 mg/m 2 iv on day 2) and carboplatin (250 mg/m 2 iv on day 2) every 4 weeks (M-VECA). All patients had bidimensionally measurable disease. Of the 32 evaluable patients, 5 (16%) obtained a complete response and 10 (31%) a partial response (response rate: 47% C.I. = 30%-64%). Grade III-IV leuko-thrombocytopenia was observed in 25%, and mucositis in 19% of cases. Nevertheless, recovery was prompt and opportune dosage reductions avoided severe toxicity in subsequent cycles in most patients. In conclusion, M-VECA is a safe and effective regimen for the treatment of patients with metastatic urothelial tumors.

AB - Transitional cell carcinoma of the urinary tract is actually considered very sensitive to cisplatin-containing regimens. Nevertheless, the generally impaired renal function and poor performance status of these patients are responsible for the severe toxicity usually occurring when cisplatin, either alone or in combination with other agents, is administered to these patients. The aim of this study was to verify the possibility of substituting carbo platin for cisplatin, and epirubicin for doxorubicin in the M-VAC regimen in order to reduce toxicity and improve patient tolerance. Thirty-five patients with advanced urothelial tract carcinoma were treated with a chemotherapeutic regimen composed of methotrexate (30 mg/m 2 iv on days 1, 15, 22), vinblastine (3 mg/m 2 iv on days 2, 15, 22), epirubicin (35 mg/m 2 iv on day 2) and carboplatin (250 mg/m 2 iv on day 2) every 4 weeks (M-VECA). All patients had bidimensionally measurable disease. Of the 32 evaluable patients, 5 (16%) obtained a complete response and 10 (31%) a partial response (response rate: 47% C.I. = 30%-64%). Grade III-IV leuko-thrombocytopenia was observed in 25%, and mucositis in 19% of cases. Nevertheless, recovery was prompt and opportune dosage reductions avoided severe toxicity in subsequent cycles in most patients. In conclusion, M-VECA is a safe and effective regimen for the treatment of patients with metastatic urothelial tumors.

KW - Bladder cancer

KW - Carbo platin

KW - Chemotherapy

KW - Epirubicin

UR - http://www.scopus.com/inward/record.url?scp=0029979213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029979213&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 154

EP - 158

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 2

ER -